Bio-Techne shareholders voted to approve the company's acquisition by Merck KGaA, Darmstadt, Germany. The Hart-Scott-Rodino waiting period expired September 18. The deal is expected to close by late 2026 or early 2027, pending remaining regulatory approvals.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
